Buy Ujjivan Financial Services: Sudip Bandopadhyay

Sudip Bandopadhyay, Market Expert told CNBC-TV18, "ForUjjivan Financial Services, the listing was good but the stock has corrected quite a bit. Obviously, the first day profit taken by the high-net worth individuals (HNIs) who have leveraged applications, so the price has come down and at current prices which is about 10 percent premium to the issue price, I think it is a good buy.""If you compare it with Equitas Holdings or other listed microfinance company like SKS Microfinance I think they are very well positioned. On the parameters which are comparable including profit and the net interest, I think they rank very well. Based on the peer comparison, Ujjivan is a buy at current level," he said."Thyrocare Technologies is an excellent company. They have done well; the listing was a great historical listing. The subscription was great but valuations at this level look a bit reach. So, I will probably wait and not buy Thyrocare at this stage."